🇺🇸 FDA
Pipeline program

REGN2810

R2810-ONC-1425

Phase 1 small_molecule terminated

Quick answer

REGN2810 for Advanced Malignancies is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Advanced Malignancies
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials